However, the features of cumulative risk of death from breast cancer were different, where 5-year and 10-years of aromatase inhibitor therapy resulted in similar risk curves but they were lower than the risk curves for 10-year tamoxifen therapy (Fig. 5). Here, CYP19A1 is linked to breast carcinoma.